Laura Alder, MD, discussed how tarlatamab’s intracranial activity compared with chemotherapy and radiation options for brain metastases in small cell lung cancer.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.